Last reviewed · How we verify
Afatinib treatment
Epidermal growth factor receptor (EGFR) inhibitor
Epidermal growth factor receptor (EGFR) inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | Afatinib treatment |
|---|---|
| Sponsor | Sheba Medical Center |
| Drug class | EGFR inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Afatinib is a potent and irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the signaling pathways that promote the growth and survival of cancer cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Rash
- Nausea
- Vomiting
- Fatigue
- Dyspnea
- Cough
- Headache
- Anorexia
- Weight loss
Key clinical trials
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer (PHASE1)
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (PHASE3)
- Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (PHASE1)
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer (PHASE2, PHASE3)
- Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck (PHASE2)
- Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afatinib treatment CI brief — competitive landscape report
- Afatinib treatment updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI